Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery (Phase 1) NCT00025181
Novel Adjuvants for Peptide-Based Melanoma Vaccines (Phase 1) NCT00028431
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma (Phase 2) NCT00032045
Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer (Phase 1) NCT00039091
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy (Phase 1) NCT00047164
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma (Phase 2) NCT00050102
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer (Phase 2) NCT00050596
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer (Phase 2) NCT00057889
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT00058279
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (Phase 1) NCT00060372
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer (Phase 1) NCT00064129
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer (Phase 1|Phase 2) NCT00075192
Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma (Phase 2) NCT00077532
Study of MDX-010 in Stage IV Breast Cancer (Phase 2) NCT00083278
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma (Phase 2) NCT00084656
CP-675,206 In Patients With Advanced Melanoma (Phase 2) NCT00086489
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (Phase 1|Phase 2) NCT00089076
CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery (Phase 1) NCT00090896
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma (Phase 3)NCT00094653
MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery (Phase 2) NCT00112580
Vaccine and Antibody Treatment of Prostate Cancer (Phase 1) NCT00113984
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide (Phase 2) NCT00135408
A Study of Anti-CTLA4 Antibody in People With Advanced Synovial Sarcoma (Phase 2) NCT00140855
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies (Phase 2) NCT00162123
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer (Phase 2) NCT00170157
Study of CP-675,206 in Refractory Melanoma (Phase 2) NCT00254579
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy (Phase 3) NCT00257205
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) (Phase 1|Phase 2) NCT00261365
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma (Phase 2) NCT00289627
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma (Phase 2) NCT00289640
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC) (Phase 2) NCT00312975
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer (Phase 1|Phase 2) NCT00323882
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma (Phase 3) NCT00324155
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma (Phase 2) NCT00357461
Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection (Phase 1) NCT00362713
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma (Phase 1) NCT00372853
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued. (Phase 2) NCT00378482
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody (Phase 1) NCT00431275
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma (Phase 2) NCT00471887
Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients (Phase 2) NCT00488995
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab () NCT00495066
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) (Phase 2) NCT00527735
A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer (Phase 1) NCT00556023
Treatment Use Study for Advanced Melanoma. () NCT00584493
A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma (Phase 1) NCT00585000
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin’s Lymphoma, ALL & CLL (Phase 1) NCT00586391
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases (Phase 2) NCT00623766
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma (Phase 3) NCT00636168
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma (Not Applicable) NCT00685750
CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer (Phase 1) NCT00702923
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (Phase 1) NCT00729950
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia (Phase 1) NCT00732186
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma (Phase 1) NCT00790010
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma (Phase 1) NCT00803374
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer (Phase 1) NCT00836407
Study of Immunotherapy to Treat Advanced Prostate Cancer (Phase 3) NCT00861614
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT00871481
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer (Phase 1) NCT00880854
Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma (Phase 1) NCT00920907
Long-term Data Collection for Subjects in MDX-010 Studies () NCT00928031
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma (Early Phase 1) NCT00972933
Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma (Phase 2) NCT01008358
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (Phase 1) NCT01024231
Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma (Phase 2) NCT01034787
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer (Phase 3) NCT01057810
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma (Phase 1) NCT01103635
Ipilimumab + Temozolomide in Metastatic Melanoma (Phase 2) NCT01119508
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (Phase 2) NCT01134614
Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer (Phase 1) NCT01165216
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma (Phase 1) NCT01176474
Neoadjuvant Ipilimumab in Prostate Cancer (Phase 2) NCT01194271
Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 (Phase 2) NCT01216696
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma (Phase 1) NCT01245556
Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer (Phase 1) NCT01255800
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (Phase 3) NCT01274338
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin (Phase 3) NCT01285609
Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (Phase 1) NCT01295827
Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (Phase 2) NCT01302496
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity (Phase 2) NCT01323517
The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer (Phase 2) NCT01331525
Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients (Phase 1) NCT01334099
THE IPI – Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease (Phase 2) NCT01355120
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (Phase 2) NCT01363206
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (Phase 2) NCT01377389
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) (Phase 1) NCT01400451
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma (Phase 1) NCT01409174
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma (Phase 1|Phase 2) NCT01409187
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer (Phase 1) NCT01445379
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy (Phase 2) NCT01449279
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone (Phase 3) NCT01450761
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) (Phase 1) NCT01454102
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer (Phase 2) NCT01471197
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) (Phase 1) NCT01472081
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (Phase 1) NCT01473940
A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 (Phase 2) NCT01480323
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma (Phase 1) NCT01489059
Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim () NCT01489423
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma (Phase 2) NCT01495988
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma (Phase 1) NCT01496807
RADVAX邃｢: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA (Phase 1|Phase 2) NCT01497808
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (Phase 2) NCT01498978
Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer (Phase 1) NCT01502592
Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer (Phase 1) NCT01510288
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma () NCT01511913
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab (Phase 3) NCT01515189
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer (Phase 2) NCT01530984
Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma (Phase 1) NCT01557114
Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma (Phase 2) NCT01565837
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma (Phase 2) NCT01585194
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy (Phase 2) NCT01585987
Doxycycline, Temozolomide and Ipilimumab in Melanoma (Phase 1|Phase 2) NCT01590082
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (Phase 1|Phase 2) NCT01592370
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Phase 1|Phase 2) NCT01604889
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-ﾎｱ2b for Melanoma (Phase 1) NCT01608594
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer (Phase 2) NCT01611558
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (Phase 1) NCT01621490
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (Phase 1) NCT01643278
A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma (Phase 2) NCT01654692
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (Phase 1|Phase 2) NCT01658878
A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma (Phase 1) NCT01672450
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma (Phase 2) NCT01673854
Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma (Phase 2) NCT01676649
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma (Phase 2) NCT01681212
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naﾃｯve Patients With Progressive Metastatic Castration-resistant Prostate Cancer (Phase 1|Phase 2) NCT01688492
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT01689870
Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma (Phase 2) NCT01689974
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer (Phase 2) NCT01693783
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma (Phase 2) NCT01696045
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (Not Applicable) NCT01701674
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma (Phase 1) NCT01703507
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (Phase 2) NCT01708941
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (Phase 2) NCT01709162
Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer (Phase 1) NCT01711515
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors (Phase 1|Phase 2) NCT01714739
Study of Ipilimumab in the Immune System (Not Applicable) NCT01715077
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (Phase 1) NCT01729806
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases (Early Phase 1) NCT01730157
Ipilimumab and Imatinib Mesylate in Advanced Cancer (Phase 1) NCT01738139
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (Phase 1|Phase 2) NCT01740297
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma (Phase 2) NCT01740401
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma (Phase 1|Phase 2) NCT01743157
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor (Phase 1) NCT01750580
Ipilimumab and Lenalidomide in Advanced Cancer (Phase 1) NCT01750983
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (Phase 1) NCT01757639
Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities () NCT01758575
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma (Phase 1) NCT01767454
Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer (Phase 1|Phase 2) NCT01769222
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) (Phase 2) NCT01783938
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy (Early Phase 1) NCT01789827
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer (Phase 2) NCT01804465
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma (Phase 1) NCT01810016
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) (Phase 2) NCT01820754
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant (Phase 1) NCT01822509
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma (Phase 2) NCT01827111
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer (Phase 1) NCT01832870
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma (Phase 1) NCT01838200
Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma (Phase 2) NCT01840007
Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) (Phase 1) NCT01840579
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) (Phase 3) NCT01844505
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma (Phase 4) NCT01856023
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) (Phase 3) NCT01866319
A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer (Phase 2) NCT01896869
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (Phase 1|Phase 2) NCT01896999
Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma (Phase 2) NCT01913691
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies (Phase 2) NCT01919619
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (Phase 2) NCT01927419
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (Phase 1|Phase 2) NCT01928394
Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer (Phase 1) NCT01935921
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (Phase 1) NCT01940809
SRS (Stereotactic Radiosurgery) Plus Ipilimumab (Phase 1) NCT01950195
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (Phase 2) NCT01950390
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma (Phase 2) NCT01970527
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized “Proof-of-principle” Phase II Study (Phase 2) NCT01973322
MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma (Phase 2) NCT01973608
A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients (Phase 1) NCT01984255
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab (Phase 1) NCT01986426
Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients (Phase 2) NCT01988077
Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients (Phase 2) NCT01990859
A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma (Phase 1) NCT01996202
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer (Phase 1) NCT01998126
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox (Phase 2) NCT02009384
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients (Phase 1|Phase 2) NCT02009397
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (Phase 3) NCT02017717
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy (Phase 2) NCT02020070
Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 (Phase 2) NCT02027935
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma (Phase 1) NCT02032810
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) (Phase 1|Phase 2) NCT02039674
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease (Phase 2) NCT02046733
Immunotherapy Study for Patients With Stage IV Melanoma (Phase 2) NCT02054520
An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (Phase 2) NCT02060188
A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. (Phase 4) NCT02068196
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies (Phase 1) NCT02070406
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT02073123
Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma (Phase 1) NCT02077114
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) () NCT02083484
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) (Phase 1|Phase 2) NCT02089685
Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma (Phase 2) NCT02094391
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery (Phase 2) NCT02097732
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma (Phase 2) NCT02107755
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer (Early Phase 1) NCT02113657
GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases (Phase 2) NCT02115139
Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma (Phase 1) NCT02115243
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma (Phase 1) NCT02117362
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer (Phase 2|Phase 3) NCT02154490
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery (Phase 2) NCT02158520
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (Phase 1) NCT02174172
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma () NCT02186249
Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation (Phase 2) NCT02196961
Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma (Phase 1) NCT02200562
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery (Phase 2) NCT02203604
Adoptive Therapy Using Antigen-Specific CD4 T-Cells (Phase 1) NCT02210104
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery (Early Phase 1) NCT02210117
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) (Phase 2) NCT02221739
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (Phase 3) NCT02224781
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) (Phase 3) NCT02231749
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors (Phase 1|Phase 2) NCT02239900
A Phase I/II Study of Intratumoral Injection of SD-101 (Phase 1|Phase 2) NCT02254772
RTA 408 Capsules in Patients With Melanoma – REVEAL (Phase 1|Phase 2) NCT02259231
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (Phase 2) NCT02259621
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma (Phase 2) NCT02272855
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (Phase 1|Phase 2) NCT02275416
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma (Phase 3) NCT02278887
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin (Phase 3) NCT02279732
Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive (Phase 2) NCT02279862
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (Phase 1|Phase 2) NCT02304458
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (Phase 2) NCT02306850
Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) (Phase 1) NCT02307149
Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (Phase 1) NCT02311920
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer (Phase 2) NCT02314169
An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself (Phase 2) NCT02320058
Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (Phase 2|Phase 3) NCT02339571
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs (Phase 2) NCT02350764
Anti窶娠D 1 Brain Collaboration for Patients With Melanoma Brain Metastases (Phase 2) NCT02374242
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer (Phase 1) NCT02381314
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (Phase 1|Phase 2) NCT02385669
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) (Phase 3) NCT02388906
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (Phase 2) NCT02397720
Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan () NCT02402699
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (Phase 2) NCT02403778
Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma (Phase 1) NCT02406183
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (Phase 1) NCT02408861
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma (Phase 1|Phase 2) NCT02413827
Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer (Phase 1) NCT02423928
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (Phase 2) NCT02428192
Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (Phase 1) NCT02437279
Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy () NCT02449837
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma (Phase 1|Phase 2) NCT02452281
Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER) (Phase 2) NCT02452294
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (Phase 1) NCT02453620
A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis (Phase 3) NCT02460068
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers (Phase 1|Phase 2) NCT02467361
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer (Phase 1) NCT02475213
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (Phase 3) NCT02477826
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (Phase 1|Phase 2) NCT02488759
PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma () NCT02492815
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (Phase 1) NCT02496208
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Phase 2) NCT02498600
Cytokine-induced Killer Study for Patients With Stage II Melanoma (Phase 2) NCT02498756
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery (Phase 2) NCT02500797
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer (Phase 2) NCT02506114
High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (Phase 3) NCT02506153
A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors (Phase 1) NCT02516527
Nivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by Surgery (Phase 2) NCT02519322
Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED (Phase 2) NCT02523313
Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) (Phase 2) NCT02530463
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer (Phase 2) NCT02536794
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy (Phase 3) NCT02538666
A Comparative Study in Chinese Subjects With Chemotherapy Naﾃｯve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine (Phase 3) NCT02545075
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) (Phase 2) NCT02553642
Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy () NCT02581228
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma (Phase 3) NCT02599402
Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy. () NCT02600143
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 (Phase 2) NCT02601014
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients (Phase 1) NCT02608437
Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases (Phase 2) NCT02621515
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer (Not Applicable) NCT02626130
Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma (Phase 2) NCT02626962
Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (Phase 2) NCT02631447
A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT02644967
An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma (Phase 2) NCT02648997
BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial (Phase 2) NCT02656706
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (Phase 1|Phase 2) NCT02658890
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (Phase 2) NCT02659059
A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma (Phase 1) NCT02659540
Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases (Phase 2) NCT02662725
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (Phase 1) NCT02668770
Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas (Phase 1) NCT02675439
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (Phase 1|Phase 2) NCT02681302
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (Phase 2) NCT02693535
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer (Phase 1|Phase 2) NCT02696993
RATIO: Rational Approach To Immuno-Oncology (Not Applicable) NCT02700971
Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer (Phase 2) NCT02701400
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (Phase 2) NCT02703623
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma (Phase 3) NCT02714218
Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (Phase 2) NCT02716272
Yervoyﾂｮ Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma () NCT02717364
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma (Phase 1) NCT02723006
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy (Phase 2) NCT02731729
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone (Phase 1|Phase 2) NCT02736123
An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread (Phase 1|Phase 2) NCT02737475
Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases () NCT02739386
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (Phase 3) NCT02741570
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma (Phase 2) NCT02743819
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (Phase 2) NCT02750514
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery (Phase 1) NCT02754856
Ipilimumab-induced Lung Toxicity: Observational Study () NCT02755233
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo (Phase 2) NCT02763761
Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study () NCT02780089
GI Complications in Cancer Immunotherapy Patients () NCT02784366
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Phase 3) NCT02785952
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma (Phase 2) NCT02794883
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery (Phase 1) NCT02812420
Ipilimumab for Head and Neck Cancer Patients (Phase 1) NCT02812524
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (Phase 2) NCT02823574
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas (Phase 1) NCT02829931
A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer (Not Applicable) NCT02833233
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (Phase 2) NCT02834013
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (Phase 1) NCT02846376
Yervoy Pregnancy Surveillance Study () NCT02854488
A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT02857569
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (Phase 3) NCT02864251
Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients (Phase 2) NCT02866383
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers (Phase 4) NCT02869789
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (Phase 3) NCT02872116
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (Phase 1) NCT02879695
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery (Phase 2) NCT02880020
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (Phase 2) NCT02888743
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (Phase 1) NCT02890329
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer (Phase 2) NCT02892734
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (Phase 3) NCT02899299
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors (Phase 1|Phase 2) NCT02904226
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma (Phase 3) NCT02905266
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases (Phase 1|Phase 2) NCT02913417
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (Phase 2) NCT02917772
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity (Phase 2) NCT02919683
IL2 Imaging in Metastatic Melanoma (Not Applicable) NCT02922283
A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma (Phase 1) NCT02922764
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers (Phase 2) NCT02923934
A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (Phase 2) NCT02935634
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab (Phase 1) NCT02935790
Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma () NCT02938728
Ipilimumab and Nivolumab in Leptomeningeal Metastases (Phase 2) NCT02939300
Real-Life Efficacy and Safety of Nivolumab in Patients With Advanced/Metastatic Renal Cell Carcinoma After Prior Therapy () NCT02940639
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases (Phase 1|Phase 2) NCT02941744
A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma (Phase 1) NCT02950766
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation (Phase 2) NCT02953457
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naﾃｯve Metastatic Kidney Cancer (Phase 2) NCT02960906
Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy (Phase 2) NCT02968303
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma (Phase 2) NCT02970981
Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (Phase 2) NCT02977052
Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (Phase 1) NCT02977156
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab (Phase 2) NCT02978443
A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma (Phase 2) NCT02982486
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (Phase 4) NCT02982954
A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors (Phase 1|Phase 2) NCT02983045
Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (Phase 2) NCT02985957
Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma and in Patients With Adjuvant Nivolumab Therapy () NCT02990611
Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (Phase 2) NCT02992912
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (Phase 2) NCT02996110
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (Phase 3) NCT02998528
An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (Phase 2) NCT03001882
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma (Phase 1|Phase 2) NCT03003637
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver (Phase 1) NCT03005002
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (Phase 1|Phase 2) NCT03009058
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas (Phase 1|Phase 2) NCT03013491
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Phase 2) NCT03026062
Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity (Phase 2) NCT03026140
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer (Phase 1|Phase 2) NCT03026166
An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma (Phase 2) NCT03029780
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery (Phase 2) NCT03033576
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (Phase 3) NCT03036098
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer (Phase 1|Phase 2) NCT03043599
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (Phase 3) NCT03048136
Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma (Phase 2) NCT03048474
Precise Local Injection of Anti-cancer Drugs Using Presage’s CIVO邃｢ Device in Soft Tissue Sarcoma (Phase 1) NCT03056599
Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature (Phase 2) NCT03061539
Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients (Phase 2) NCT03065179
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (Phase 3) NCT03068455
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Participants With Metastatic Uveal Melanoma (Phase 1) NCT03068624
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma (Phase 2) NCT03070392
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma (Phase 2) NCT03071406
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC (Phase 2) NCT03075423
BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer (Phase 2) NCT03083691
Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer (Phase 2) NCT03091491
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma (Phase 2) NCT03097939
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab (Phase 1) NCT03098160
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer (Phase 2) NCT03101566
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer (Phase 2) NCT03104439
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors (Phase 1|Phase 2) NCT03110107
Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma (Phase 2) NCT03117309
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy (Phase 2) NCT03122522
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies (Phase 1|Phase 2) NCT03126110
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients (Phase 2) NCT03126461
An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (Phase 2) NCT03130959
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer (Early Phase 1) NCT03132467
SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma (Phase 1|Phase 2) NCT03138161
A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (Phase 3) NCT03138512
Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases () NCT03140137
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (Phase 3) NCT03141177
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (Phase 3) NCT03143153
Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer (Phase 1) NCT03144778
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer (Phase 2) NCT03146650
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab (Phase 2) NCT03149159
A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma (Phase 2) NCT03153085
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer (Phase 2) NCT03158129
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma (Phase 1|Phase 2) NCT03161756
Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer (Early Phase 1) NCT03162731
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread () NCT03165409
A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan () NCT03165422
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) (Phase 1|Phase 2) NCT03168464
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment (Phase 2) NCT03171064
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer (Phase 2) NCT03172624
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (Phase 2) NCT03177239
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer (Phase 2) NCT03190265
Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (Phase 1|Phase 2) NCT03195478
Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer (Phase 1) NCT03203304
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) (Phase 2) NCT03203473
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors (Phase 1) NCT03203876
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer (Phase 2) NCT03204812
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (Phase 3) NCT03215706
Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) (Phase 2) NCT03219671
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma (Phase 2) NCT03219775
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma (Phase 2) NCT03220009
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer (Phase 2) NCT03222076
Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer (Phase 1) NCT03223155
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma (Not Applicable) NCT03225365
Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies (Phase 1) NCT03233139
Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma (Phase 1) NCT03233152
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (Phase 2) NCT03235245
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies (Phase 1|Phase 2) NCT03241173
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma (Phase 2) NCT03241186
Nivolumab Plus Ipilimumab in Thyroid Cancer (Phase 2) NCT03246958
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (Phase 1|Phase 2) NCT03251924
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC (Phase 2) NCT03256136
Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. (Phase 2) NCT03262779
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation (Phase 1|Phase 2) NCT03271047
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma (Phase 2) NCT03274258
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma (Phase 1) NCT03283046
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer (Phase 1|Phase 2) NCT03287674
TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (Phase 1) NCT03293784
Adoptive Cell Therapy Across Cancer Diagnoses (Phase 1|Phase 2) NCT03296137
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma (Phase 1|Phase 2) NCT03297463
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma (Phase 2) NCT03297593
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (Phase 2) NCT03297606
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) (Phase 3) NCT03302234
Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL (Phase 1|Phase 2) NCT03305445
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery (Phase 2) NCT03307616
Expanded Access for Pembrolizumab (MK-3475) () NCT03311542
Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma (Phase 2) NCT03313323
Study of Adverse Renal Effects of Immune Checkpoints Inhibitors () NCT03316417
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (Phase 1|Phase 2) NCT03326258
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors (Phase 2) NCT03333616
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (Phase 1) NCT03335540
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients (Phase 2) NCT03342417
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208) (Phase 1|Phase 2) NCT03347123
TNF in Melanoma Patients Treated With Immunotherapy (Not Applicable) NCT03348891
Interest of iRECIST Evaluation for DCR for Evaluation of Patients With Deficient MMR and /or MSI Metastatic Colorectal Cancer Treated With Nivolumab and Ipilimumab (Phase 2) NCT03350126
Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer (Phase 3) NCT03351361
ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint) () NCT03354936
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) (Phase 1|Phase 2) NCT03354962
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (Phase 2) NCT03355976
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma (Phase 2) NCT03367715
An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread (Phase 1|Phase 2) NCT03369223
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer (Phase 1) NCT03373188
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer (Phase 2) NCT03373760
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer (Phase 1|Phase 2) NCT03377023
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread (Phase 1|Phase 2) NCT03377361
Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions () NCT03387540
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (Phase 1) NCT03388632
Phase III Trial of (LCT) After Nivolumab and Ipilimumab (Phase 3) NCT03391869
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma (Phase 2) NCT03396952
Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Phase 1|Phase 2) NCT03404960
Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (Phase 2) NCT03406247
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac – Patients With Small Cell Lung Cancer (SCLC) (Phase 2) NCT03406715
A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV) (Phase 1) NCT03407105
CAVATAKﾂｮ and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) (Phase 1) NCT03408587
Biomarkers of Immune-Related Toxicity () NCT03409016
Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer (Phase 2) NCT03409198
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer (Phase 3) NCT03409614
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (Phase 2) NCT03409848
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer (Phase 2) NCT03416244
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors (Phase 2) NCT03420521
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (Phase 1) NCT03422094
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer (Phase 1) NCT03425292
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC (Phase 2) NCT03425331
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma (Phase 1) NCT03425461
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer (Phase 2) NCT03430063
Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naﾃｯve, Recurrent Glioblastoma (Phase 2) NCT03430791
Combination of Chemoradiation With Immunotherapy in Inoperable ﾅ都ophageal Cancer (Phase 2) NCT03437200
Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy () NCT03438279
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence (Phase 2) NCT03443856
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed (Phase 1) NCT03444753
A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) (Phase 3) NCT03445533
Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom () NCT03448497
Long Term Quality of Life in Melanoma Patients in Netherlands () NCT03450876
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers (Phase 1) NCT03452332
Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition () NCT03453892
Improved Therapy Response Assessment in Metastatic Brain Tumors () NCT03458455
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (Phase 1|Phase 2) NCT03459222
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas () NCT03460782
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (Phase 2) NCT03461952
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer (Phase 2) NCT03468985
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (Phase 3) NCT03469960
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver (Phase 2) NCT03472586
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer (Phase 1) NCT03477864
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction () NCT03492242
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (Phase 1) NCT03493932
Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer (Phase 1) NCT03507699
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis (Phase 1) NCT03508570
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients (Phase 1) NCT03509584
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) (Phase 2) NCT03510871
REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer (Phase 3) NCT03515629
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy (Phase 2) NCT03520491
Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma (Phase 2) NCT03521830
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Phase 1|Phase 2) NCT03522584
ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors (Phase 1|Phase 2) NCT03525795
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes (Early Phase 1) NCT03526185
Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC (Phase 1) NCT03527251
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma (Phase 2) NCT03528408
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer (Phase 1) NCT03532217
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma (Phase 1) NCT03538314
Peri-Operative Ipilimumab+Nivolumab and Cryoablation Versus Standard Care in Women With Triple-negative Breast Cancer (Phase 2) NCT03546686
Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) (Phase 2) NCT03548428
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma (Phase 2) NCT03552380
Melanoma Metastasized to the Brain and Steroids (Phase 2) NCT03563729
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma (Phase 1) NCT03565406
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (Phase 2) NCT03570619
Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (Phase 2) NCT03573947
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer (Phase 1|Phase 2) NCT03575793
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer (Phase 1|Phase 2) NCT03581487
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (Phase 2) NCT03591731
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma (Phase 1) NCT03597282
PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma (Phase 2) NCT03598816
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome (Phase 1) NCT03600155
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer (Phase 2) NCT03601455
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma (Phase 1|Phase 2) NCT03604978
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (Phase 2|Phase 3) NCT03604991
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner (Phase 1|Phase 2) NCT03618134
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease (Phase 2) NCT03618641
A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck (Phase 2) NCT03620123
Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients (Not Applicable) NCT03627026
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab (Phase 2) NCT03638141
A Study of a Personalized Neoantigen Cancer Vaccine (Phase 1|Phase 2) NCT03639714
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma (Phase 2) NCT03646617
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer (Phase 2) NCT03647969
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients (Phase 2) NCT03650894
Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer (Phase 2) NCT03651271
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) (Phase 1|Phase 2) NCT03663166
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread () NCT03663946
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (Phase 2) NCT03668119
A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy (Phase 2) NCT03670056
Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma (Phase 1|Phase 2) NCT03682276
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer (Phase 1) NCT03690986
INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma (Not Applicable) NCT03692338
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors (Phase 2) NCT03693014
Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors (Phase 2) NCT03693846
A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen. () NCT03695835
Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy (Phase 3) NCT03700905
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma (Phase 1) NCT03707457
Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab (Phase 1) NCT03707808
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma (Phase 2) NCT03711188
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy (Phase 2) NCT03719131
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression (Phase 2) NCT03724968
RACIN in Patients With Advanced TIL-negative Solid Tumors (Phase 1) NCT03728179
Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma (Phase 2) NCT03728465
A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US () NCT03732560
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers (Phase 1|Phase 2) NCT03749460
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome (Phase 2) NCT03767439
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma (Phase 1) NCT03769155
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer (Phase 1|Phase 2) NCT03776487
Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer – a Combination Immunotherapy Phase Ib Study. (Phase 1) NCT03784040
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer (Phase 2) NCT03789110
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (Phase 3) NCT03793166
Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer (Phase 1) NCT03798639
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma (Phase 2) NCT03799445
CAcTUS – Circulating Tumour DNA Guided Switch (Phase 2) NCT03808441
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (Phase 1) NCT03816332
Anetumab Ravtansine With Nivolumab, Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Mesothelin Positive Advanced Pancreatic Cancer (Phase 1) NCT03816358
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (Phase 2) NCT03818685
An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (Phase 2) NCT03823625
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (Phase 1) NCT03829111
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer (Phase 2) NCT03832621
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study (Phase 1|Phase 2) NCT03844256
Radiation and Combination Immunotherapy for Melanoma (Phase 2) NCT03850691
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) (Phase 2) NCT03865082
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (Phase 2) NCT03866382
Autoantibodies in Treatment With Immune Checkpoint Inhibitors (AUTENTIC) () NCT03868046
An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer (Phase 3) NCT03873402
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain (Phase 2) NCT03873818
A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (Phase 1) NCT03878524
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer (Phase 2|Phase 3) NCT03879122
Optune Device – TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis (Phase 2) NCT03903640
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT (Phase 1) NCT03912064
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (Phase 2) NCT03914300
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma (Phase 1) NCT03922880
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma (Phase 1) NCT03929029
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (Phase 3) NCT03937219
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (Phase 2) NCT03945773
Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis (Phase 1|Phase 2) NCT03949153
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (Phase 1|Phase 2) NCT03953235
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers (Phase 1) NCT03956680
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma (Phase 1|Phase 2) NCT03958383
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma (Phase 2) NCT03959293
Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial (Phase 3) NCT03977571
A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment (Phase 1) NCT03978611
Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy (Phase 1) NCT03982121
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (Phase 2) NCT03989362
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors (Phase 2) NCT03993379
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma (Phase 2) NCT03999749
IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma (Phase 1) NCT04003649
Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma (Phase 2) NCT04006262
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma (Phase 2) NCT04007588
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (Phase 3) NCT04008030
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer (Phase 1) NCT04013542
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab (Phase 2) NCT04013854
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers (Phase 1|Phase 2) NCT04021043
Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma (Phase 1|Phase 2) NCT04021420
A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (Phase 3) NCT04026412
ImmunoPET With an Anti-CD8 Imaging Agent (Phase 1|Phase 2) NCT04029181
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (Phase 2) NCT04034927
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (Phase 3) NCT04039607
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors (Phase 2) NCT04042753
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (Phase 1|Phase 2) NCT04043195
A Prospective Observational Study of Renal Cell Cancer Patients Treated With Nivolumab Plus Ipilimumab in the Real World Setting in Japan () NCT04043975
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (Phase 1|Phase 2) NCT04060407
Perioperative Chemotherapy vs Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG (Phase 2) NCT04062656
Study of ARRY-614 Plus Either Nivolumab or Ipilimumab (Phase 1|Phase 2) NCT04074967
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors (Phase 2) NCT04079712
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (Phase 2) NCT04080804
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma (Phase 2) NCT04088500
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (Phase 2) NCT04090710
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma (Phase 2) NCT04090775
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma (Phase 2) NCT04091750
Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (Phase 2) NCT04093323
Microbiome Immunotherapy Toxicity and Response Evaluation () NCT04107168
Phase IB/II Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (Phase 1|Phase 2) NCT04109729
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer (Phase 1) NCT04117087
Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma (Phase 2) NCT04118166
Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer (Phase 2) NCT04124601
Nivolumab/Ipilimumab in Second Line CUP-syndrome (Phase 2) NCT04131621
A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2-Breast Cancer That Has Spread (Phase 1) NCT04132817
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (Phase 1|Phase 2) NCT04133948
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. (Phase 2) NCT04134182
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics () NCT04136470
PhIb Study Evaluating Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC (Phase 1) NCT04141644
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) for People With Recurrent Glioblastoma With Elevated Mutational Burden (Phase 2) NCT04145115
AImmune – Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient’s Response to Immunotherapies. () NCT04145232
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response () NCT04146064
CaboCHECK – Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study () NCT04147143
Detection and identification of bacteria in clinical samples by 16S rRNA gene sequencing:comparison of two different approaches in clinical practice
https://www.microbiologyresearch.org/docserver/fulltext/jmm/61/4/483_jmm030387.pdf?expires=1570540556&id=id&accname=guest&checksum=5420BE74E3BA950EA45B92F013CBE211
Efficient Nucleic Acid Extraction and 16S rRNA Gene Sequencing for Bacterial Community Characterization
https://www.jove.com/video/53939/efficient-nucleic-acid-extraction-16s-rrna-gene-sequencing-for
Using a 16S rRNA Sequence to Identify a Bacterial Isolate (2017/10/03 Oxford Academic (Oxford University Press))
What Is 16s rRNA sequencing？ (2018/08/01 CD Genomics)
https://www.youtube.com/watch?v=3UHiveJ1jzM
理論からストーリーへ : 構成主義的グラウンデッド・セオリー法とは Shifting from Theory-Generalization to Story-Construction : An Overview of Constructivist Grounded Theory Approach 抱井 尚子（青山学院大学基機関リポジトリ）
An estimation of the number of cells in the human bodyEva Bianconi, Allison Piovesan, Federica Facchin, Alina Beraudi, Raffaella Casadei, Flavia Frabetti, Lorenza Vitale, Maria Chiara Pelleri, Simone Tassani, Francesco Piva, Soledad Perez-Amodio, Pierluigi Strippoli & Silvia Canaider Annals of Human BiologyVolume 40, 2013 – Issue 6 Pages 463-471 Published online: 05 Jul 2013 DOI:10.3109/03014460.2013.807878
学術誌を評価する指標としてジャーナルインパクトファクター（クラリベイト社がデータベースWeb of Scienceに基づいて算出）が有名ですが、同様のデータベースScopusを擁するエルゼビアは新たな学術誌評価のための指標としてCiteScoreなるものを2016年に発表しました。インパクトファクターに比べると、ほとんど耳にすることがないと思います。
In December 2016, Elsevier launched a new journal metric, CiteScore, that takes direct aim at the hegemony of the Impact Factor, a product of Clarivate Analytics (formerly part of Thomson Reuters.) The two companies already have competing bibliographical citation databases in Scopus (Elsevier) and the Web of Science (Clarivate).
The Impact Factor has had a long reign in academe. Beginning in 1975 as a byproduct of the Science Citation Index, it provided a unique, objective means of rating journals based on their citations and quickly became a standard measure of journal quality. When someone says they want a journal’s impact factor they really mean the Impact Factor from Journal Citation Reports (JCR) and nothing else.
CiteScore 2016: How does it work?
Undoubtedly Elsevier will always have better records on their own journals than others used to generate CiteScore.
The Web of Science, across all databases, indexes 32,925 journals vs. the 22,256 in Scopus.
We carefully weed out any predatory and non-peer-reviewed journals
（December 14, 2016 CiteScore: A Non-Rival for the Journal Impact Factor clarivate.com）
2018年ノーベル化学賞は酵素進化工学のFrances H. Arnold博士, ファージディスプレイのGeorge P. Smith博士、Sir Gregory P. Winter博士の3氏に授与されました。
BREAKING NEWS:
The Royal Swedish Academy of Sciences has decided to award the #NobelPrize in Chemistry 2018 with one half to Frances H. Arnold and the other half jointly to George P. Smith and Sir Gregory P. Winter. pic.twitter.com/lLGivVLttB
“In almost no time we can reject half our applicant pool just by looking at their cover letters,” says Susan Lord, associate professor of electrical engineering at the University of San Diego. (The Basics of Cover Letter Writing By Richard M. Reis MARCH 03, 2000 THE CHRONICLE OF HIGHER EDUCATION)
カバーレターの構成
そのポジションで何が求められているのかをリサーチして、それに関係する内容だけを書くこと。
Research the responsibilities associated with each of these positions, and include only information relevant to the specific position – don’t waste valuable space on irrelevant experiences. (Cover letter for a faculty position, BROAD INSTITUTE)
I am writing to apply for the tenure-track position in mathematics as advertised on the Employment Information in the Mathematical Sciences List. (hwpi.harvard.edu)
I am writing to apply to the tenure-track position of Assistant Professor in the Department of Bioengineering at the R1 University Y (RUY). (career.ucsf.edu)
I am writing to apply for the position of Assistant Professor in Structural Engineering beginning Fall 2014, as advertised on your department website. (Cover Letters for Academic Positions grad.illinois.edu)
I am writing in response to your notice in the October MLA Job Information List for the
position of Assistant Professor of Spanish. … (vpul.upenn.edu)
I am writing to apply for the open tenure-track faculty position in the English Department at New Parkland Univeristy. … (livecareer.com)
参考
各大学が、学生やポスドクの就職支援を目的として応募書類作成のコツを紹介しています。
Cover letter for a faculty position, BROAD INSTITUTE マサチューセッツ工科大学
